These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 26365140)
21. Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease. Kulshreshtha A; Piplani P Neurol Sci; 2016 Sep; 37(9):1403-35. PubMed ID: 27250365 [TBL] [Abstract][Full Text] [Related]
22. Cognitive dysfunctions induced by a cholinergic blockade and Aβ 25-35 peptide are attenuated by salvianolic acid B. Kim DH; Park SJ; Kim JM; Jeon SJ; Kim DH; Cho YW; Son KH; Lee HJ; Moon JH; Cheong JH; Ko KH; Ryu JH Neuropharmacology; 2011 Dec; 61(8):1432-40. PubMed ID: 21903108 [TBL] [Abstract][Full Text] [Related]
23. The GABAergic system as a therapeutic target for Alzheimer's disease. Calvo-Flores Guzmán B; Vinnakota C; Govindpani K; Waldvogel HJ; Faull RLM; Kwakowsky A J Neurochem; 2018 Sep; 146(6):649-669. PubMed ID: 29645219 [TBL] [Abstract][Full Text] [Related]
24. Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders. Kaufer DI Curr Psychiatry Rep; 1999 Oct; 1(1):78-84. PubMed ID: 11122908 [TBL] [Abstract][Full Text] [Related]
25. How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story. Richardson A; Galvan V; Lin AL; Oddo S Exp Gerontol; 2015 Aug; 68():51-8. PubMed ID: 25481271 [TBL] [Abstract][Full Text] [Related]
26. Mutation-induced loss of APP function causes GABAergic depletion in recessive familial Alzheimer's disease: analysis of Osaka mutation-knockin mice. Umeda T; Kimura T; Yoshida K; Takao K; Fujita Y; Matsuyama S; Sakai A; Yamashita M; Yamashita Y; Ohnishi K; Suzuki M; Takuma H; Miyakawa T; Takashima A; Morita T; Mori H; Tomiyama T Acta Neuropathol Commun; 2017 Jul; 5(1):59. PubMed ID: 28760161 [TBL] [Abstract][Full Text] [Related]
28. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. Grossberg GT Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of Drp1 Ameliorates Synaptic Depression, Aβ Deposition, and Cognitive Impairment in an Alzheimer's Disease Model. Baek SH; Park SJ; Jeong JI; Kim SH; Han J; Kyung JW; Baik SH; Choi Y; Choi BY; Park JS; Bahn G; Shin JH; Jo DS; Lee JY; Jang CG; Arumugam TV; Kim J; Han JW; Koh JY; Cho DH; Jo DG J Neurosci; 2017 May; 37(20):5099-5110. PubMed ID: 28432138 [TBL] [Abstract][Full Text] [Related]
30. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368 [TBL] [Abstract][Full Text] [Related]
31. The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Friedman JI; Adler DN; Davis KL Biol Psychiatry; 1999 Nov; 46(9):1243-52. PubMed ID: 10560029 [TBL] [Abstract][Full Text] [Related]
33. [Neuropathology of Alzheimer's disease and mild cognitive impairment]. López OL; DeKosky ST Rev Neurol; 2003 Jul 16-31; 37(2):155-63. PubMed ID: 12938076 [TBL] [Abstract][Full Text] [Related]
34. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Levy ML; Cummings JL; Kahn-Rose R Gerontology; 1999; 45 Suppl 1():15-22. PubMed ID: 9876214 [TBL] [Abstract][Full Text] [Related]
35. Cognitive subdomain responses to galantamine in Alzheimer's disease. Song J; Ahn IS; Kang HS; Myung W; Lee Y; Woo SY; Ku HM; Hwang TY; Carroll BJ; Kim DK J Nerv Ment Dis; 2014 Mar; 202(3):253-9. PubMed ID: 24566512 [TBL] [Abstract][Full Text] [Related]
36. Drug development in dementia. Cunningham EL; Passmore AP Maturitas; 2013 Nov; 76(3):260-6. PubMed ID: 23707728 [TBL] [Abstract][Full Text] [Related]
37. Neuroprotective action of diazepam at very low and moderate doses in Alzheimer's disease model rats. Pilipenko V; Narbute K; Pupure J; Rumaks J; Jansone B; Klusa V Neuropharmacology; 2019 Jan; 144():319-326. PubMed ID: 30408486 [TBL] [Abstract][Full Text] [Related]
38. [Therapy of Alzheimer disease]. Kovács T Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816 [TBL] [Abstract][Full Text] [Related]